Harrington Discovery Institute and the American Society for Clinical Investigation seek nominations to recognize an outstanding achievement by a physician-scientist
CLEVELAND, July 25, 2022 /PRNewswire/ -- National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application.
The Harrington Prize, which carries a $20,000 honorarium, is a collaboration between Harrington Discovery Institute at University Hospitals in Cleveland, Ohio and the American Society for Clinical Investigation (ASCI), one of the nation's oldest and most respected medical honor societies. Harrington Discovery Institute is a nonprofit institute dedicated to helping physician-scientists accelerate promising discoveries into medicines for unmet needs.
Both organizations recognize the challenges associated with translating academic discoveries into medicines, and they are eager to highlight those who have navigated the path successfully or whose work has led to novel treatments.
A committee composed of members of the Harrington Discovery Institute Scientific Advisory Board and the ASCI Council will review the nominations and select the awardee. In addition to the honorarium, the 2023 recipient will deliver the Harrington Prize Lecture at the 2023 Joint Meeting of the Association of American Physicians (AAP), the ASCI, and the American Physician Scientists Association (APSA); will lecture at the 2023 Harrington Discovery Institute Symposium; and will publish a personal essay in the Journal of Clinical Investigation.
- Nominee must have an MD or MD/PhD (or equivalent).
- Deadline for nominations is September 12, 2022.
- Multiple nominations from an institution are welcomed.
- Teams are accepted for a nomination, but a primary nominee is required.
- Nomination guidelines can be found at HarringtonDiscovery.org/Prize.
- 2014: Harry Dietz, MD, Johns Hopkins University, for his contributions to the understanding of the biology and treatment of Marfan syndrome, a disorder leading to deadly aneurysms in children and adults.
- 2015: Douglas R. Lowy, MD, The National Cancer Institute, in recognition of his discoveries that led to the development of the Human Papillomavirus vaccine to prevent cervical cancer.
- 2016: Jeffrey M. Friedman, MD, PhD, The Rockefeller University, for his discovery of leptin, which controls feeding behavior and is used to treat related clinical disorders.
- 2017: Jointly awarded to Daniel J. Drucker, MD, Mount Sinai Hospital, Canada, Joel F. Habener, MD, Massachusetts General Hospital, and Jens J. Holst, MD, DMSc, University of Copenhagen, Denmark, for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes.
- 2018: Helen H. Hobbs, MD, UT Southwestern Medical Center, for the discovery of the link between a gene mutation (PCSK9) and lower levels of LDL, which has improved the treatment of high cholesterol.
- 2019: Carl H. June, MD, University of Pennsylvania, for advancing the clinical application of CAR T therapy for cancer treatment, and for his sustained contributions to the field of cellular immunology.
- 2020: Stuart H. Orkin, MD, Harvard University, for breakthrough discoveries on red blood cells that offer new treatments for patients with sickle cell disease and beta-thalassemia, which are among the most common genetic disorders.
- 2021: Jointly awarded to Warren J. Leonard, MD, NHLBI and John J. O'Shea, MD, NIAMS, NIH, for their respective contributions to the field of immunology, from fundamental discovery to therapeutic impact.
- 2022: Jointly awarded to James E. Crowe, Jr., MD, Vanderbilt University, and Michel C. Nussenzweig, MD, PhD, The Rockefeller University, for their groundbreaking work in immunology, which has elucidated fundamental principles of the human immune response and enabled the use of human antibodies to treat COVID-19.
View original content:
SOURCE Harrington Discovery Institute